Monoclonal Antibodies for Multiple Sclerosis Treatment

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Monoclonal antibodies (mAbs) have become vital in medical therapy since the late 20th century.
• Neurology has significantly benefited from mAb therapeutics, integrating them into treatment plans for various conditions.
• Multiple sclerosis (MS) is a key neurological disease where mAbs are established and emerging treatments.

Purpose of the Study:

• To review current data on monoclonal antibodies used in multiple sclerosis treatment.
• To discuss monoclonal antibodies in clinical development for multiple sclerosis.
• To highlight the growing role of antibody-based therapies in managing multiple sclerosis.

Main Methods:

• Literature review of scientific articles and clinical trial data.
• Analysis of approved and investigational monoclonal antibody therapies for multiple sclerosis.
• Synthesis of information on efficacy, safety, and future potential.

Main Results:

• Several monoclonal antibodies are currently licensed for multiple sclerosis treatment.
• Numerous other monoclonal antibodies are undergoing clinical development for MS.
• Monoclonal antibodies represent a significant and expanding therapeutic avenue for multiple sclerosis.

Conclusions:

• Monoclonal antibodies are a cornerstone in modern multiple sclerosis management.
• Ongoing research and development promise further advancements in antibody-based MS therapies.
• The future of multiple sclerosis treatment will heavily involve monoclonal antibody drugs.